A cancer diagnosis is hard enough without a second worry about whether treatment is even possible. So let's be clear up front: MDR1-affected dogs receive chemotherapy. The mutation doesn't rule it out. What it does is change the dosing of certain agents — and that's a calculation a veterinary oncologist makes as a matter of course.
The chemotherapy drugs that matter
Several chemotherapy agents are P-glycoprotein substrates, which means MDR1-affected dogs handle them differently. WSU groups these among the drugs that require dose reduction in affected dogs to avoid severe toxicity:
- Doxorubicin — a widely used agent across several canine cancer protocols.
- Vincristine — common in lymphoma and other protocols.
- Vinblastine — in the same chemical family as vincristine.
- Paclitaxel — grouped by WSU with the chemotherapy agents requiring dose reduction.
For each of these, WSU's guidance is that affected dogs should receive reduced doses to avoid severe toxicity. The reason traces back to the same mechanism as every other MDR1 drug: without a working P-glycoprotein pump, the drug accumulates where it shouldn't, and the dog experiences more intense effects than a normal dog would at the same dose.
Why this is never a do-it-yourself decision
Chemotherapy dosing is precise, individualised, and entirely the domain of a veterinary oncologist. Unlike the household drugs on the MDR1 list — where an owner might reach for loperamide without thinking — chemotherapy is only ever administered under specialist supervision. So the practical job for an owner is simpler than it sounds: make sure the oncology team knows your dog's MDR1 status before the protocol is set.
If your dog has been tested, share the genotype. If it hasn't and it's an at-risk breed, raise it — testing before a chemotherapy protocol is a reasonable and common step, because it lets the team dose precisely rather than conservatively. See how to test your dog.
What good looks like
A well-run oncology plan for an MDR1-affected dog looks much like any other: the same drugs, adjusted doses, careful monitoring. Dogs with the mutation complete chemotherapy protocols successfully when their genotype is known and accounted for. The mutation is information, not an obstacle.
If you're at the start of this road, the most helpful thing you can do is bring your dog's MDR1 status — known or suspected — into the very first conversation with the oncologist. Everything downstream follows from that.